Leap Therapeutics, headquartered in Cambridge, Mass., acquired New Hope, Pa.-based Flame Biosciences. The primary focus of the merger was for Leap to pick up Flame’s FL-301, a clinical-stage anti-Claudin18.2 monoclonal antibody.